

**Preliminary Amendment, Communication Requesting  
Entry of Sequence Listing, and Proposed Drawing Corrections**

Page 4

Applicant(s): Watowich et al.

Serial No. 09/981,286

Confirmation No. 4993

Filed: October 15, 2001

For: DRUG DISCOVERY METHODS

**Remarks**

The specification is amended to identify two nucleic acid sequences with SEQ ID NOs. The specification is also amended to correct a typographical error and is supported by the specification at, for instance, page 11, lines 18-28.

The drawings are amended to identify SEQ ID NOs., and to correct inadvertently omitted text.

**Conclusion**

The Examiner is invited to contact Applicants' Representatives at the below-listed telephone number, if there are any questions regarding this Preliminary Amendment or if prosecution of this application may be assisted thereby.

**CERTIFICATE UNDER 37 C.F.R. 1.8:**

The undersigned hereby certifies that this paper is being deposited in the United States Postal Service, as first class mail, in an envelope addressed to: Assistant Commissioner for Patents, Attn: Missing Parts, Washington, D.C. 20231, on this 28th day of January, 2002.

David L. Provence  
David L. Provence

Respectfully submitted,

Watowich et al.

By  
Muetting, Raasch & Gebhardt, P.A.  
P.O. Box 581415  
Minneapolis, MN 55458-1415  
Telephone: (612) 305-1220  
Facsimile: (612) 305-1228

January 28, 2002  
Date

By: David L. Provence  
David L. Provence  
Reg. No. 43,022  
Direct Dial (612) 305-1005